Interview with Kleiner Device Labs

By Equifund

This webinar is brought to you by Equifund Technologies, LLC.

Earlier this week, we had the chance to interview Mike Hughes – Chief Commercial Officer at Kleiner Device Labs (KDL).

The call lasted ~60 minutes, and we had the chance to dive into several different topics, like…

  • How value based care could change everything in healthcare
  • The shift to ASC and outpatient centers
  • The rise in minimally invasive surgical techniques
  • The problems facing the healthcare system today
  • How KDL is positioned to help ASCs with the most profitable segment of their business…
  • And what’s to come in 2022 for KDL.

After you watch the interview, if you have any additional questions for the KDL management team, please use the Q&A forum at the bottom of their offering page.

Download the Kleiner Interview webinar slide deck here.

Considering an Investment in Kleiner Device Labs?

If so, you’ll want to review their offering listed on the Equifund Crowd Funding Portal by going here. 

Currently, KDL can raise up to $1.07 million under their current Form-C filing (they are currently at ~$850k in commitments) which means this round is almost full.

More Articles:

📈Gold: The best performing asset of 2023?

Equifund May 26, 2023

You’re probably sick and tired of hearing about the de-dollarization narrative, the debt ceiling shakedown, and Janet Yellen’s June 1st “hard deadline,” where we risk

Don't make another private market investment without reading this...

The 5 Mistakes

investors make that crush returns

Download this free report now:

Just enter your name & email to access this report for free.

By submitting your email address you will receive access to this report and a free subscription to Equifund’s private investment newsletter. You can unsubscribe at any time and read more about our privacy policy here.

More Articles:

Advertisement:

Kleiner Device Labs

  • Patented devices that allow spine surgery to be less painful and less expensive with better outcomes​

Investment Highlights:

  • 1

    Proprietary devices that could revolutionize spinal surgery and greatly improve success rates, reduce pain, and lower costs.

  • 2

    Over 20 patents have been issued to protect the company's technologies.

  • 3

    Just received FDA clearance for their next-generation KG2 spinal fusion technology.

Find Out More

Pre-Investment Agreement

The next 8 slides will allow us to process your investment. Note that these next steps are a legal requirement – Thank you for your patience and financial support of this investment opportunity. Jordan Gillissie – CEO

Before we execute the investment, it’s important for us to make sure you’re comfortable and knowledgeable in early stage investing. We want to make sure that you:

    • Received and have reviewed the education materials sent to you.
    • UNDERSTAND; that there are restrictions on your ability to cancel your investment commitment and obtain a return of your investment.
    • KNOW; It may be difficult to resell securities acquired under Regulation Crowdfunding.
    • AGREE; investing in securities offered and sold in reliance on section 4(a)(6) of the Securities Act involves risk. Investors should not invest any funds unless he or she can afford to lose the entire amount of his or her investment. Your investment may not work out, and you must be in a financial condition to bear the loss.
  • Hidden
  • Hidden
  • Hidden
  • Hidden

We are currently upgrading our system. If you click submit and the process does not continue in a few seconds, please refresh this page manually, and click Invest Now again and you should be moved on to the next step.

Complete Your Registration

By verifying your account you agree with our terms of use, privacy policy and pre-dispute arbitration agreement. Please complete the registration process by clicking the link below:

Verify Your Email

Please wait a few minutes while we create your account. An email will be sent to you shortly to confirm your admittance. Should the email be delivered to your spam or promotions folder, we recommend you move it to your inbox and mark Equifund as a safe sender.

If you have not received the email in 5 minutes, please click here to have it resent.

Questions? Our customer service team is always here to help – 1-866-338-3004

Enter your email address to get instant access to the video: